Symphony Financial, Ltd. Co. Vertex Pharmaceuticals Inc Transaction History

Symphony Financial, Ltd. Co.

  • $608 Million
  • Q3 2024

A detailed history of Symphony Financial, Ltd. Co. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Symphony Financial, Ltd. Co. holds 1,390 shares of VRTX stock, worth $567,370. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,390
Previous 2,201 36.85%
Holding current value
$567,370
Previous $1.03 Million 37.34%
% of portfolio
0.11%
Previous 0.19%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024
SELL
$460.0 - $505.78 $373,060 - $410,187
-811 Reduced 36.85%
1,390 $646,000
Q2 2024

Jul 17, 2024
SELL
$392.81 - $485.53 $53,029 - $65,546
-135 Reduced 5.78%
2,201 $1.03 Million
Q1 2024

Apr 17, 2024
BUY
$407.69 - $446.08 $592,781 - $648,600
1,454 Added 164.85%
2,336 $976,000
Q4 2023

Jan 18, 2024
SELL
$343.0 - $410.68 $507,640 - $607,806
-1,480 Reduced 62.66%
882 $358,000
Q3 2023

Nov 07, 2023
SELL
$338.18 - $362.46 $276,969 - $296,854
-819 Reduced 25.75%
2,362 $821,000
Q2 2023

Jul 12, 2023
BUY
$314.42 - $351.91 $129,855 - $145,338
413 Added 14.92%
3,181 $1.12 Million
Q1 2023

May 03, 2023
SELL
$283.23 - $323.1 $7,080 - $8,077
-25 Reduced 0.9%
2,768 $872,000
Q4 2022

Jan 26, 2023
BUY
$285.76 - $321.48 $798,127 - $897,893
2,793 New
2,793 $0
Q2 2022

Jul 18, 2022
SELL
$234.96 - $292.55 $148,024 - $184,306
-630 Reduced 27.04%
1,700 $477,000
Q1 2022

May 13, 2022
BUY
$221.42 - $260.97 $515,908 - $608,060
2,330 New
2,330 $643,000
Q3 2020

Oct 09, 2020
SELL
$255.65 - $303.1 $255,650 - $303,100
-1,000 Closed
0 $0
Q2 2020

Jul 08, 2020
BUY
$225.48 - $295.8 $225,480 - $295,800
1,000 New
1,000 $290,000

Others Institutions Holding VRTX

# of Institutions
1,724
Shares Held
221M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Symphony Financial, Ltd. Co. Portfolio

Follow Symphony Financial, Ltd. Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Symphony Financial, Ltd. Co., based on Form 13F filings with the SEC.

News

Stay updated on Symphony Financial, Ltd. Co. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email